194 related articles for article (PubMed ID: 34360933)
1. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis.
Choi HS; Kim YK; Yun PY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360933
[TBL] [Abstract][Full Text] [Related]
2. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
3. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
[TBL] [Abstract][Full Text] [Related]
9. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
10. Cultivation of Head and Neck Squamous Cell Carcinoma Cells with Wound Fluid Leads to Cisplatin Resistance via Epithelial-Mesenchymal Transition Induction.
Meyer TJ; Stöth M; Moratin H; Ickrath P; Herrmann M; Kleinsasser N; Hagen R; Hackenberg S; Scherzad A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922946
[TBL] [Abstract][Full Text] [Related]
11. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
La Fleur L; Johansson AC; Roberg K
PLoS One; 2012; 7(9):e44071. PubMed ID: 23049743
[TBL] [Abstract][Full Text] [Related]
12. Effects of the administration of epidermal growth factor receptor specific inhibitor cetuximab, alone and in combination with cisplatin, on proliferation and apoptosis of Hep-2 laryngeal cancer cells.
Bussu F; Pozzoli G; Giglia V; Rizzo D; Limongelli A; De Corso E; Graziani C; Paludetti G; Navarra P; Almadori G
J Laryngol Otol; 2014 Oct; 128(10):902-8. PubMed ID: 25236402
[TBL] [Abstract][Full Text] [Related]
13. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.
O'Keefe RA; Bhola NE; Lee DS; Johnson DE; Grandis JR
PLoS One; 2020; 15(1):e0227261. PubMed ID: 31914141
[TBL] [Abstract][Full Text] [Related]
15. Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition.
Liao J; Yang Z; Carter-Cooper B; Chang ET; Choi EY; Kallakury B; Liu X; Lapidus RG; Cullen KJ; Dan H
Clin Exp Metastasis; 2020 Apr; 37(2):283-292. PubMed ID: 32020377
[TBL] [Abstract][Full Text] [Related]
16. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
[TBL] [Abstract][Full Text] [Related]
17. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
19. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC).
Moncharmont C; Guy JB; Wozny AS; Gilormini M; Battiston-Montagne P; Ardail D; Beuve M; Alphonse G; Simoëns X; Rancoule C; Rodriguez-Lafrasse C; Magné N
Oncotarget; 2016 Jul; 7(30):47738-47749. PubMed ID: 27374096
[TBL] [Abstract][Full Text] [Related]
20. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
